As debulking surgery is the primary outcome of most patients with advanced ovarian cancer, different approaches have been developed to improve outcomes for ovarian cancer patients, including the incorporation of targeted therapy, such as anti-VEGF agents, immunotherapy, and PARP inhibitors [38]. This evidence concerns the gene VEGFA and ovarian cancer.